PARSIPPANY, New Jersey, USA & TEL AVIV, Israel – June 8, 2026
Teva Pharmaceuticals has unveiled new real-world and long-term clinical data demonstrating the sustained benefits of AUSTEDO® (deutetrabenazine) and AUSTEDO XR® in the treatment of tardive dyskinesia (TD), reinforcing the importance of early diagnosis and continued therapy for patients living with the chronic movement disorder. Presented at Psych Congress Elevate 2026, the comprehensive data package included findings from the IMPACT-TD Registry, the long-term RIM-TD study, and a caregiver-focused education initiative, providing new insights into symptom improvement, functional outcomes, and disease recognition. The results further strengthen Teva’s leadership in TD treatment and underscore the company’s commitment to advancing patient care through evidence-based approaches that address both clinical symptoms and quality-of-life challenges associated with the condition. As awareness of TD continues to grow among healthcare providers and patient communities, the latest findings offer important evidence supporting sustained treatment strategies and proactive disease management.
Real-World Data Show Meaningful Improvements with AUSTEDO
One of the most significant findings came from the IMPACT-TD Registry, the largest real-world study of tardive dyskinesia. Researchers evaluated patients with mild TD symptoms who initiated treatment with AUSTEDO or AUSTEDO XR, revealing clinically meaningful improvements across multiple measures. At three months, all participants experienced reductions in Abnormal Involuntary Movement Scale (AIMS) scores while maintaining psychiatric stability, highlighting the therapy’s effectiveness even among patients with less severe disease. Importantly, individuals who reported impairment in activities of daily living, psychosocial functioning, speech, and communication at baseline also demonstrated measurable improvements following treatment.
These findings challenge the notion that mild TD requires limited intervention and suggest that earlier treatment may help prevent progression while improving daily functioning and overall quality of life. Investigators emphasized that involuntary movements often have broader consequences extending beyond physical symptoms, affecting confidence, communication, and social engagement.
Long-Term Treatment Delivers Continued Clinical Benefits
Advertisement
Additional data from the three-year RIM-TD open-label study highlighted the value of maintaining treatment over time. Analysis showed that more than 50% of patients achieved clinically meaningful improvements in AIMS scores within the first 15 weeks of treatment, while an additional 23% of patients achieved significant symptom improvement after week 15. These results suggest that continued therapy can provide incremental benefits beyond the initial treatment period and reinforce the importance of long-term management strategies.
The findings offer valuable guidance for clinicians treating TD, indicating that patients who do not achieve optimal responses immediately may still experience meaningful symptom reduction with ongoing treatment. Researchers noted that the progressive improvement observed throughout the study supports a patient-centered approach focused on sustained therapy and regular clinical evaluation rather than early discontinuation when immediate responses are not observed.
Closing the Diagnosis Gap in Tardive Dyskinesia
Teva also presented findings highlighting the role of caregiver education in improving disease recognition and diagnosis. The study demonstrated that providing TD-specific educational resources through digital platforms encouraged critical discussions between caregivers, patients, and healthcare providers. Within six months, 53% of at-risk individuals discussed TD with a healthcare professional, while 34% subsequently received a formal TD diagnosis. These results underscore the importance of awareness initiatives in addressing the significant diagnosis gap that continues to exist in tardive dyskinesia. Company leaders emphasized that improving recognition of early symptoms remains essential to ensuring timely intervention and optimizing long-term outcomes.
Together, the IMPACT-TD, RIM-TD, and caregiver education findings provide a comprehensive view of the patient journey, from diagnosis through sustained treatment. As the understanding of tardive dyskinesia continues to evolve, Teva’s latest research reinforces the value of AUSTEDO and AUSTEDO XR as important therapeutic options capable of delivering durable symptom control, improved daily functioning, and enhanced quality of life for individuals living with this challenging neurological condition.
Source: Teva Pharmaceuticals press release
